Safety, pharmacokinetics, and preliminary pharmacodynamics of 1% and 3% diclofenac vaginal hydrogel for the treatment of primary dysmenorrhea: a randomized, placebo controlled trial
Abstract
Objective: To describe the safety and pharmacokinetics (PK) of a novel 1% and 3% diclofenac vaginal hydrogel among healthy premenopausal women with symptomatic primary dysmenorrhea. Preliminary efficacy was an exploratory objective. Methods: A Phase 1, randomized, double-blind, placebo-controlled, clinical trial was conducted. Safety was measured by treatment emergent adverse events (TEAEs) after both a single and three daily vaginal doses. Vaginal fluid and plasma PK of diclofenac were measured after a single dose. Participants recorded daily dysmenorrhea associated pain (DAP) scores in a control cycle and during treatment with the three daily doses of study product, and recorded use of rescue pain medications and non-pharmacologic pain-relieving measures. Results: Vaginal diclofenac 1% and 3% was well tolerated, with no significant difference in the frequency or severity of TEAEs compared to placebo vaginal hydrogel (p values > 0.13). Median maximum plasma diclofenac concentrations were 36.4 ng/mL and 57.6 ng/mL for the 1% and 3% dose, respectively, and were mostly below the limit of quantification by 48 h post single dose. Median vaginal fluid diclofenac concentrations peaked at 2 h for the 1% formulation (1105 µg/mL) and 8 h for the 3% formulation (4415 µg/mL). Participants in the 1% diclofenac group had non-significant reductions in DAP scores post-treatment, but sample size and variability of DAP scores limited statistical comparisons of this exploratory endpoint.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.